Proprietary Antibody
Drug Conjugates

ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers.

ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.

Selective targeting means fewer side effects for patients and ADC Therapeutics believes the unique PBD mode of action will result in a superior efficacy and resistance profile.

ADC Therapeutics Announces Positive Pre-clinical Results for Two of its Novel ADCs at the American Society of Hematology Conference

5 December 2015

Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US – 5 December 2015

– ADC Therapeutics (ADCT), the oncology drug development company, today presented pre-clinical results for both ADCT-301 and ADCT-402, its novel Antibody Drug Conjugates (ADCs) in hematological tumours at the 57th American Society of Hematology (ASH) Annual Meeting, December 5-8, in Orlando, Florida. ADCT-301 is currently in Phase I for lymphoma and leukemia. Yesterday ADCT announced that it has received IND clearance from the FDA to begin two Phase I clinical trials with ADCT-402 in hematological tumors.

ADCT-301 combines HuMax®-TAC, a human monoclonal antibody targeting CD25 (the alpha chain of the IL-2 receptor) created by Genmab A/S, with a dimeric pyrrolobenzodiazepine (PBD) warhead. The data confirm the mechanism of action of ADCT-301 and provide relevant pharmacodynamic assays for use in clinical development.

ADCT-402 is an anti-CD19 PBD-conjugate, with presented data demonstrating potent and specific in vitro and in vivo anti-tumor activity against CD19-positive hematological tumors as well as excellent tolerability.

Dr Patrick van Berkel, Senior Vice President Research & Development at ADC Therapeutics, said: “We are highly encouraged by these data which demonstrate the potential of ADCT-301 and ADCT-402. As we continue development, early indications are that our PBD-based ADCs could offer superior efficacy with a reduced resistance profile for the treatment of hematological tumors.”

The pre-clinical studies referenced above were conducted jointly by ADC Therapeutics, Spirogen (a division of AstraZeneca) and University College London, London.

 

- ENDS -

 

Notes to Editors

 

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics Sarl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADC Therapeutics has its head office in Lausanne, Switzerland and through subsidiaries has its R&D laboratories in London, UK, its clinical development team in New Jersey, USA, and its manufacturing team based in San Francisco, USA. With its industry leading management team and board of directors, ADC Therapeutics is a leader in the development of PBD-based ADCs.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for its Second Novel Antibody Conjugate ADCT-402 against Lymphomas and Leukemia

4 December 2015

Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US – 4 December 2015

– ADC Therapeutics SA (ADCT or the “Company”), the oncology drug development company focused on Antibody Drug Conjugates (ADCs), today announced that it has received clearance from the US Food and Drug Administration (FDA) to begin clinical trials with ADCT-402, a novel antibody drug conjugate targeting CD19, a cell-surface antigen, which is over-expressed in many patients with B-cell non-Hodgkin Lymphoma (NHL) and B-cell Acute Lymphoblastic Leukemia (ALL). ADCT plans to initiate Phase I clinical trials in both NHL and ALL.

ADCT-402 combines a humanized monoclonal antibody targeting CD19 with a pyrrolobenzodiazepine (PBD) warhead. In preclinical in vivo models, ADCT-402 exhibited strong dose-dependent anti-tumor activity against CD19-positive leukemic and lymphoma cell lines at low single doses, and it outperformed other CD19 targeted ADCs currently in clinical development.

The first of the Phase I clinical trials for patients with B-cell NHL will commence at eight leading oncology centres in the USA and two centres in the United Kingdom. The initial study will evaluate the tolerability, safety, pharmacokinetics and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell NHL. Subject to study results, ADCT intends to rapidly expand the numbers of patients in the trial and expand the number of participating clinical centres.

Dr. Owen O’Connor, Professor of Medicine and Experimental Therapeutics, and the Director of the Center for Lymphoid Malignancies, and Co-Program Director of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, is the Principal Investigator for this Phase I study.

Dr. O’Connor said: “There is significant unmet medical need for patients with relapsed or refractory disease in B-cell NHL. An ADC targeting CD19 with a potent PBD warhead, is a sensible approach in this difficult to treat population. We are delighted to be working with ADC Therapeutics to bring this potential treatment to patients.”

The second study, a Phase 1 trial for patients with relapsed or refractory B-cell ALL will commence simultaneously at 10 centres in the USA and EU to evaluate the tolerability, safety, pharmacokinetics and anti-tumor activity of ADCT-402 in this patient population. Dr. Nitin Jain, Assistant Professor in the Leukemia Department at MD Anderson Cancer Center in Houston, Texas, is the Principal Investigator for this Phase 1 study said: “We have made significant strides treating patients with B-Cell ALL but we are still seeking new treatment modalities to improve the prognosis for patients. We are excited to working with ADC Therapeutics on this program.”

Dr. Jay M. Feingold, Senior Vice President and Chief Medical Officer at ADC Therapeutics said: “This is the second ADC we have advanced into clinical development in the past eight months. Preclinical data suggests that ADCT-402 may have significant activity against B-cell NHL and ALL and we are pleased to progress our pipeline by beginning these two clinical studies and, hopefully, to bring significant benefit to patients with these diseases.”

 

- ENDS -

 

Notes to Editors

 

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics Sarl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADC Therapeutics has its head office in Lausanne, Switzerland and through subsidiaries has its R&D laboratories in London, UK, its clinical development team in New Jersey, USA, and its manufacturing team based in San Francisco, USA. With its industry leading management team and board of directors, ADC Therapeutics is a leader in the development of PBD-based ADCs.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Therapeutics Announces Expanded Board with Appointment of Highly Experienced Non-Executive Directors

28 September 2015

Dr Hans-Peter Wild and Jacques Theurillat join the Board

Lausanne, Switzerland, London, UK and Murray Hill, New Jersey, US - 28 September 2015

– ADC Therapeutics (ADCT), the oncology drug development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that Dr Hans-Peter Wild and Jacques Theurillat have been appointed to its Board of Directors as Non-Executive Directors. The appointments follow ADCT’s recent $80m financing and further strengthens ADCT’s board as it matures as a Company.

Dr Wild is the owner and Chairman of the Wild Group and has built multiple global businesses, including Wild Flavours GmbH; one of the world’s leading producers and suppliers of natural ingredients for the food and drink industry, a global consumer goods business under the CapriSun® brand, and a processing units manufacturer for the food and drink industry. Dr Wild has an Honours degree in Law from the University of Heidelberg and gained his doctorate from the Faculty of Law at the University of Mannheim. He also holds a Master in Business Administration from the University of Mannheim and is an Honorary Senator of the University of Heidelberg.

As an independent Non Executive Director, Mr Theurillat brings to the Board extensive experience in strategy development, finance and commercial operations. He has been CEO of Ares Life Sciences AG and previously served as CEO and Chairman of Albea Pharmaceuticals AG. He also had an extensive career at Serono, which spanned roles such as Chief Financial Officer, Deputy Chief Executive Officer and Senior Executive Vice President, Strategic Corporate Development. Mr Theurillat holds Bachelor of Law Degrees from Madrid University and Geneva University, a Master’s Degree in Finance from Centro Estudios Financieros, Madrid and a Swiss Federal Tax Expert Diploma.

Dr Chris Martin, CEO of ADCT, said: “We have made rapid progress since our formation just three years ago and, as we invest in the development of our significant pipeline of ADC therapeutics, it is important that we expand our board to help steer the Company forwards. Jacques and Hans-Peter bring very considerable experience to the board and we welcome their strategic insight, and commercial and financial experience.”

Dr Martin joined the Company full time as its CEO in June, having played a key role in the Company’s formation and strategy as a member of its Board of Directors since the Company’s founding in 2012. Previously Dr. Martin served as CEO of Spirogen and was a member of MedImmune’s Leadership Team.

The other members of the Board of ADC Therapeutics are: Dr. Peter B. Corr (Chairman), Stephen Evans-Freke, Michael Forer (Messrs. Corr, Evans-Freke, and Forer of founding investor Auven Therapeutics), Dr Bahija Jallal (Executive Vice President of AstraZeneca and head of MedImmune), and independent Non-Executive Director Dr Barrie Ward (former CEO of Kudos).

 

-ENDS-

 

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics Sarl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADCT was established in 2012 by private equity firm Auven Therapeutics. In 2013, AstraZeneca acquired an equity stake in the Company and entered into a corporate partnership for two ADC programs. It is located in Lausanne, Switzerland, and utilizes laboratory facilities at Queen Mary Bioenterprises Innovation Centre, London, UK. ADCT has manufacturing and clinical studies managed from its US offices in San Francisco and New Jersey.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Therapeutics Secures $80m Financing to Progress its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology

2 September 2015

Lausanne, Switzerland and London, UK and Murray Hill, New Jersey, US, 2 September 2015

– ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $80 million through a private placement of equity. New investors include leading European and US-based investors alongside founding investor Auven Therapeutics and participation from AstraZeneca.

The proceeds will be used to progress ADCT’s product portfolio, including ADCT-301 for lymphoma and leukemia now in Phase I and a collaboration to develop up to two ADCs for commercialisation with MedImmune, the global biologics research and development arm of AstraZeneca. ADCT’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with highly potent pyrrolobenzodiazepine (PBD)-based warheads. ADCT anticipates having seven drug candidates in human clinical trials in 2017.

ADCT was established in 2012 by private equity firm Auven Therapeutics. In 2013, AstraZeneca/MedImmune acquired an equity stake in the Company and entered into a collaboration for two ADC programs.

The Company has built and will be expanding its highly experienced R&D team in the UK, as well as legal, finance and EU clinical teams in Switzerland, and regulatory, clinical and manufacturing teams in the US. ADCT works closely with a number of specialist partners in Europe and the US for regulatory, clinical trial management and manufacturing activities.

Dr. Chris Martin, a recognised leader in the ADC space, joined ADCT fulltime in June of this year as Chief Executive Officer, having played a key role in the formation and strategy of ADCT as a member of its Board of Directors. Previously Dr. Martin served as CEO of Spirogen and was a member of MedImmune’s Leadership Team.

Commenting on the financing, Dr Martin said: “The significant advances we have made in progressing our pipeline of ADCs have been recognized by this financing round. In a major milestone for the Company, our first ADC candidate drug entered the clinic earlier this year and we are on track to file for our second IND with the FDA by the end of October.”

Dr. Peter B. Corr, Chairman of the Board of ADCT and co-founder and Managing General Partner of Auven Therapeutics added: “The quality of investors we have been able to attract and the size of this investment round, just over three years since the Company was founded, is a great endorsement of our strategy and potential. This financing provides the funds required to aggressively develop our pipeline of proprietary ADCs with best-in-class PBD-based warheads and linkers as an important part of the next-generation of cancer drugs, with the potential to impact cancer patients worldwide.”

The Company was advised by Dr. Christoph Ladanyi, co-founder and Managing Director of BLMS Capital, and its corporate legal counsel Homburger.

 

- ENDS -

 

Notes to Editors

 

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics Sarl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADCT was established in 2012 by private equity firm Auven Therapeutics. In 2013, AstraZeneca acquired an equity stake in the Company and entered into a corporate partnership for two ADC programs. It is located in Lausanne, Switzerland, and utilizes laboratory facilities at Queen Mary Bioenterprises Innovation Centre, London, UK. ADCT has manufacturing and clinical studies managed from its US offices in San Francisco and New Jersey.

 

About Auven Therapeutics (www.auventx.com)

 

Auven Therapeutics is a global private equity firm that acquires and pursues accelerated development of breakthrough therapeutic drugs prior to licensing them to commercial partners. Auven’s in-house team of senior pharmaceutical development executives establishes the clinical regulatory, manufacturing and commercial strategies for all its products and oversees their execution. Auven was founded in 2007 by Stephen Evans-Freke and Dr. Peter B. Corr and maintains operations in Lausanne, Ft. Lauderdale, Bermuda, and the US Virgin Islands.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

22 June 2015

Lausanne, Switzerland and London, UK, 22 June 2015

– ADC Therapeutics Sarl (the Company or ADCT), the oncology research and development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced the appointment of Dr. Chris Martin as its Chief Executive Officer.

Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca in October 2013 for $440 million in upfront and deferred consideration. Dr. Martin continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Dr. Martin will continue to advise Medimmune as a consultant.

Dr. Martin played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding. He is a recognised leader in the Antibody Drug Conjugates space, and his leadership of Spirogen led to Spirogen being awarded the Best Scientific Innovation Award in 2014 and Dr Martin being voted by industry peers the winner of the overall ‘Individual Input to the Industry in 2013/2014’ at the World ADC Awards.

Dr. Martin replaces Michael Forer who has served as CEO of the Company since its formation. Mr. Forer is a Partner in the private equity firm Auven Therapeutics and was the lead investor on behalf of Auven for its majority investments in both Spirogen Ltd and ADC Therapeutics. Mr. Forer becomes Vice Chairman of ADC Therapeutics, and will continue to work with the Company as Executive Vice President focused on its public markets capital strategy, business and finance activities.

Dr. Peter B. Corr, Chairman of the Board of ADCT and co-founder and Managing General Partner of Auven Therapeutics, said: “Chris played an important role together with Michael Forer in the founding of ADC Therapeutics, and its business plan to develop proprietary PBD-based ADCs under license from Spirogen. He has contributed significantly to the business both as a board member and shareholder, and we are delighted that he has now joined the Company as CEO as we move forward with 7 PBD-based ADCs into clinical development over the next two years. We believe that PBD-based ADCs are the next-generation of cancer drugs with the potential to make a large impact on cancer patients worldwide.”

Dr. Martin said: “The Company is entering an exciting phase of clinical development, having recently filed its first IND for a clinical trial in lymphoma and its second IND to be filed later this year. Michael has been an important supporter to the success of both Spirogen and ADC Therapeutics, and I thank him for his leadership to-date. I look forward to working even more closely with the ADCT team as well as with our investors and collaborators, to realize the potential of our ADC drugs.”

 

- ENDS -

 

Notes to Editors

 

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics Sarl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADCT was established in 2012 by private equity firm Auven Therapeutics. In 2013, AstraZeneca acquired an equity stake in the Company and entered into a corporate partnership for two ADC programs. It is located in Lausanne, Switzerland, and utilizes laboratory facilities at Queen Mary Bioenterprises Innovation Centre, London, UK. ADCT has manufacturing and clinical studies managed from its US offices in San Francisco and New Jersey.

 

About Auven Therapeutics (www.auventx.com)

 

Auven Therapeutics is a global private equity firm that acquires and pursues accelerated development of breakthrough therapeutic drugs prior to licensing them to commercial partners. Auven’s in-house team of senior pharmaceutical development executives establishes the clinical regulatory, manufacturing and commercial strategies for all its products and oversees their execution. Auven was founded in 2007 by Stephen Evans-Freke and Dr. Peter B. Corr and maintains operations in Lausanne, Ft. Lauderdale, Bermuda, and the US Virgin Islands.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Terapeutics Presented Positive Pre-clinical Activity of its Novel Anti-CD22 Antibody-Drug Conjugate at the American Association for Cancer Research (AACR) Annual Meeting

19 April 2015

Lausanne, Switzerland and London, UK, 22 June 2015

– ADC Therapeutics Sarl (the Company or ADCT), the oncology research and development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced the appointment of Dr. Chris Martin as its Chief Executive Officer.

Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca in October 2013 for $440 million in upfront and deferred consideration. Dr. Martin continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Dr. Martin will continue to advise Medimmune as a consultant.

Dr. Martin played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding. He is a recognised leader in the Antibody Drug Conjugates space, and his leadership of Spirogen led to Spirogen being awarded the Best Scientific Innovation Award in 2014 and Dr Martin being voted by industry peers the winner of the overall ‘Individual Input to the Industry in 2013/2014’ at the World ADC Awards.

Dr. Martin replaces Michael Forer who has served as CEO of the Company since its formation. Mr. Forer is a Partner in the private equity firm Auven Therapeutics and was the lead investor on behalf of Auven for its majority investments in both Spirogen Ltd and ADC Therapeutics. Mr. Forer becomes Vice Chairman of ADC Therapeutics, and will continue to work with the Company as Executive Vice President focused on its public markets capital strategy, business and finance activities.

Dr. Peter B. Corr, Chairman of the Board of ADCT and co-founder and Managing General Partner of Auven Therapeutics, said: “Chris played an important role together with Michael Forer in the founding of ADC Therapeutics, and its business plan to develop proprietary PBD-based ADCs under license from Spirogen. He has contributed significantly to the business both as a board member and shareholder, and we are delighted that he has now joined the Company as CEO as we move forward with 7 PBD-based ADCs into clinical development over the next two years. We believe that PBD-based ADCs are the next-generation of cancer drugs with the potential to make a large impact on cancer patients worldwide.”

Dr. Martin said: “The Company is entering an exciting phase of clinical development, having recently filed its first IND for a clinical trial in lymphoma and its second IND to be filed later this year. Michael has been an important supporter to the success of both Spirogen and ADC Therapeutics, and I thank him for his leadership to-date. I look forward to working even more closely with the ADCT team as well as with our investors and collaborators, to realize the potential of our ADC drugs.”

 

- ENDS -

 

Notes to Editors

 

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics Sarl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADCT was established in 2012 by private equity firm Auven Therapeutics. In 2013, AstraZeneca acquired an equity stake in the Company and entered into a corporate partnership for two ADC programs. It is located in Lausanne, Switzerland, and utilizes laboratory facilities at Queen Mary Bioenterprises Innovation Centre, London, UK. ADCT has manufacturing and clinical studies managed from its US offices in San Francisco and New Jersey.

 

About Auven Therapeutics (www.auventx.com)

 

Auven Therapeutics is a global private equity firm that acquires and pursues accelerated development of breakthrough therapeutic drugs prior to licensing them to commercial partners. Auven’s in-house team of senior pharmaceutical development executives establishes the clinical regulatory, manufacturing and commercial strategies for all its products and oversees their execution. Auven was founded in 2007 by Stephen Evans-Freke and Dr. Peter B. Corr and maintains operations in Lausanne, Ft. Lauderdale, Bermuda, and the US Virgin Islands.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas

16 March 2015

Lausanne, Switzerland and London, UK, 16 March 2015

– ADC Therapeutics Sarl (the “Company”), the oncology drug development company focused on Antibody Drug Conjugates (ADCs), today announced that it has filed an Investigational New Drug application (IND) with the US Food and Drug Administration as it moves its pipeline into clinical development. The IND is for a Phase I clinical trial for ADCT-301, a novel antibody drug conjugate targeting CD25, a cell-surface antigen, which is over-expressed in many patients with lymphomas.

The Phase I clinical trial will commence at four leading oncology centres in the USA, and can expand into two centres in the United Kingdom. The initial up to 58 patient adaptive designed dose-escalation study, will evaluate the tolerability, safety, pharmacokinetics and antitumor activity of ADCT-301 in patients with relapsed or refractory Hodgkin’s and Non-Hodgkin’s lymphoma. Subject to study results, ADC Therapeutics intends to rapidly expand the numbers of patients in the trial and the participating clinical centres.

ADCT-301 combines HuMax®-TAC™, a monoclonal antibody targeting CD25 (the alpha chain of the IL-2 receptor) created by Genmab A/S, with a pyrrolobenzodiazepine (PBD) warhead. In preclinical in vivo models, ADCT-301 exhibited strong dose-dependent anti-tumor activity against CD25-positive cell lines at low single doses. It also outperformed AdcetrisTM (brentuximab vedotin), an ADC approved for treatment of Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma, in animal models. In preclinical studies the PBD warhead has been shown to be a highly potent killer of cancer cells even when such cancer cells are resistant to current best therapies.

Dr. Steven M. Horwitz, Medical Oncologist at Memorial Sloan Kettering Cancer Center in New York City, is the Principal Investigator for the Phase I study. Dr. Horwitz said: “There is significant unmet medical need for patients with relapsed or refractory disease in Hodgkin’s and non-Hodgkin’s Lymphoma. An ADC targeting CD25, which is widely expressed in lymphomas, is a very rational therapeutic approach and could have very broad activity. We are delighted to be working with ADC Therapeutics to bring this potential treatment to patients.”

Michael Forer, Chief Executive Officer of ADC Therapeutics said: “The filing of our first IND is a significant milestone for ADC Therapeutics. We are delighted to be working with Memorial Sloan Kettering and other leading clinical centers. We believe this is a significant endorsement of the prospects for ADCT-301. In addition, we expect to file four more INDs with additional proprietary ADCs over the next two years as we continue to build our clinical pipeline.”

ADC Therapeutics has a license to the PBD warheads from Spirogen now owned by MedImmune, and the HuMax®-TAC™ antibody was developed by Genmab under license from Medarex. In June 2013, Genmab and ADC Therapeutics entered into a Collaboration and License Agreement for the development of ADCT-301, and Genmab holds a 25% ownership share in ADCT-301. No other financial terms were disclosed.

 

- ENDS -

 

Notes to Editors

 

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics Sarl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADCT was established in 2012 by private equity firm Auven Therapeutics. In 2013, AstraZeneca acquired an equity stake in the Company and entered into a corporate partnership for two ADC programs. It is located in Lausanne, Switzerland, and utilizes laboratory facilities at Queen Mary Bioenterprises Innovation Centre, London, UK. ADCT has manufacturing and clinical studies managed from its US offices in San Francisco and New Jersey.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Therapeutics Expands Team

30 September 2014

Lausanne, Switzerland and London, UK, 30 September, 2014

ADC Therapeutics (ADCT, a portfolio company of Auven Therapeutics) the oncology drug development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced a significant expansion of its team as the Company’s first ADCs enter clinical development.

New team members include:

Dr Jay Feingold joins as Chief Medical Officer and Head of Oncology Clinical Development. Dr Feingold has more than 25 years of industry, academic and medical experience and was most recently Vice President, US Medical Affairs and Chairman Global Medical Affairs Oversight Committee at Daiichi Sankyo. Prior to this, he served as Vice President of Clinical Development, Global Therapy Area Director, Oncology at Wyeth.

Dr Michael Mulkerrin joins as Head of CMC (Chemistry Manufacturing and Control). Dr Mulkerrin has more than 20 years of industry experience in biologics manufacturing, most recently as Vice President, Process Development and Manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech.

Dr Simon Chivers joins as Head of Toxicology. Dr. Chivers has more than 15 years of industry experience, most recently as Global Head Biologics Safety Assessment and Executive Director at Novartis and has had prior senior roles at AstraZeneca, Syngenta and Quintiles.

Dr Lisa Skelton joins as Senior Project Manager for ADCT’s lead program ADCT-301 which is scheduled to enter clinical development in early 2015. Dr. Skelton has over 20 years of industry experience, most recently as Associate Director, Programme Management at Norgine and Senior Program Manager at Amgen.

Dr Karin Havenith joins as Senior Bioanalytical Scientist to head ADCT’s bioanalytical group. Dr. Havenith was Principal Scientist at J&J Janssen Crucell and Principal Scientist at Genmab where she specialized in the development of bioanalytical assays for antibody therapeutics.

Dr Francesca Zammarchi joins the scientific team as Cancer Biologist, having spent eight years as a Research Associate in the Molecular Pharmacology and Chemistry Department of Memorial Sloan Kettering Cancer Center, New York.

Ms. Dulce Gonçalves joins to serve as Corporate Counsel. Ms Gonçalves has over 12 years experience in pharmaceutical law and was most recently Senior Legal Counsel, Global Product Strategy and Commercialization, at Novartis.

Mr. Stéphane Henchoz joins as Director of Finance, bringing more than 20 years pharmaceutical industry finance experience, most recently working at Merck Serono.

Michael Forer, Chief Executive Officer of ADC Therapeutics, said: “The quality of individuals and depth of experience that we have been able to attract demonstrates the significant potential for our PBD-based ADCs. This expansion underlines the progress we have made since the Company was established in early 2012. We continue to advance our pipeline of programs into clinical development with our lead program, ADCT-301, scheduled to enter clinical development in early 2015.”

Dr. Peter B. Corr, Chairman of the Board and co-founder and Managing General Partner of ADCT’s founding majority investor, Auven Therapeutics, added “ADCs are an important class of the next-generation of cancer drugs, and with our best in class PBD warheads and linkers these agents should have a profound impact for patients with cancer. With the addition over the last year of AstraZeneca, as both an investor in and corporate partner of ADCT, the Company is well funded, and with these new personnel now has a world class team in place to support our plan of having multiple proprietary ADCs in clinical development over the coming two years.”

Notes to Editors

 

ADC Therapeutics sarl (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As its PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market. The company was formed in 2012 with a $50m commitment from private equity firm Auven Therapeutics (previously known as Celtic Therapeutics). ADCT has a strategic collaboration with Spirogen Ltd, also an Auven Therapeutics’ portfolio company, for the supply of warhead chemistries and R&D services. It operates a virtual business model based in Lausanne, Switzerland.

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast, lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linkers chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune.

ADCT was established in 2012 by private equity firm Auven Therapeutics. In 2013, AstraZeneca acquired an equity stake in the Company and entered into a corporate partnership for two ADC programs. ADCT has more than $100 million in committed capital to develop its pipeline of proprietary antibody drug conjugates.

About pyrrolobenzodiazepine (PBD) warhead technology

 

PBDs have been shown by researchers at a number of pharmaceutical companies to be dramatically more efficacious than first generation warhead chemistries in a wide range of preclinical models of different tumor types. In 2013 ADCT and Spirogen published data showing that the Herceptin monoclonal antibody conjugated with a PBD warhead yields a large proportion of Complete Responses in HER2-positive cancer models, including low HER2-expressers. In contrast, the first generation ADC-targeting HER2, now approved for refractory HER2-positive breast cancer, only slows tumor cell growth in these models although significantly longer than stand-alone Herceptin. Seattle Genetics announced the filing of an IND on its first PBD-warheaded ADC, developed under a license from Spirogen, in 2013, and recently stated they intended to file an IND on a second PBD-warheaded ADC this year.

About Auven Therapeutics (www.auventx.com)

Auven Therapeutics is a global private equity firm that acquires and pursues accelerated development of breakthrough therapeutic drugs prior to licensing them to commercial partners. Auven’s in-house team of senior pharmaceutical development executives establish the clinical, regulatory, manufacturing and commercial strategies for all its products and oversees their execution. Auven was founded in 2007 by Stephen Evans-Freke and Dr. Peter B. Corr, and maintains operations in Lausanne, London, New York, Bermuda, and the U.S. Virgin Islands.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

19 May 2014

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

Lausanne, Switzerland and London, UK, May 19 2014 – ADC Therapeutics (ADCT), an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, announced today that it has selected its first IND candidate under its joint development agreement with MedImmune, the global biologics research and development arm of AstraZeneca.

This follows the October 2013 announcement in which MedImmune entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADCT’s antibody-drug conjugate programs in preclinical development.

ADCT-401 targets Prostate-Specific Membrane Antigen (PSMA) a cell-surface antigen specifically expressed by prostate cancer cells. ADCT-401 comprises an anti-PSMA monoclonal antibody coupled with a pyrrolobenzodiazepine (PBD) warhead using a proprietary linker licensed from London-based Spirogen, a wholly owned subsidiary of MedImmune. Initial clinical studies will focus on hormone-refractory prostate cancer and an IND filing is anticipated in 2015.

“We are excited by the preclinical efficacy data we have seen with ADCT-401 in a number of in vivo models of prostate cancer. These data have encouraged us to continue development of this unique ADC for the treatment of refractory prostate cancer. ADCT-401 was constructed and tested by the joint ADCT and Spirogen teams, and we are very pleased with the outcome,” said Dr. Peter B. Corr, Chairman of ADCT and Co-Founder and Managing General Partner of Auven Therapeutics, the private equity firm behind the formation of ADCT and its majority shareholder.

The PSMA-specific J591 antibody in ADCT-401 was developed by Dr. Neil H. Bander, the Bernard & Josephine Chaus Professor of Urologic Oncology and Director of Urological Oncology Research at the Weill-Cornell Medical College, New York. Dr. Bander is also Chairman of ADCT’s Scientific Advisory Board. PSMA is a cell-surface antigen expressed by virtually all prostate cancer cells, including metastases, and also in the blood vessels that feed many other tumor types, but is rarely expressed in normal cells.

“PSMA is an ideal target for an ADC therapeutic strategy because it is unparalleled in its prostate cancer specificity, its high density of expression and its very efficient internalization,” said Dr. Neil Bander. “If the preclinical efficacy and safety studies translate into the clinic, ADCT-401 has the potential to be a breakthrough therapy in the treatment of advanced, refractory prostate cancers. I am delighted that the ADCT and MedImmune teams have combined their efforts to advance it into patients as quickly as possible,” he added.

This will be ADCT’s second ADC program into the clinic from its pipeline of eleven programs with an IND filing expected in the first of these programs by the end of this year.

“We are optimistic that continued investigations of ADCT-401 in patients with prostate cancer will deliver the results we expect. The program is a testament to the close teamwork, commitment to scientific excellence and sense of urgency shared between the MedImmune and ADC Therapeutics teams on this project,” said Stephen Evans-Freke, Co-founder and Managing General Partner of Auven Therapeutics.

The pre-clinical development of ADCT-401 is being managed by a team of scientists based in laboratories at the Queen Mary Bioenterprises Innovation Centre, London which, being co-located with Spirogen, enables close co-operation between the two groups.

Notes to Editors

 

ADC Therapeutics sarl (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As its PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market. The company was formed in 2012 with a $50m commitment from private equity firm Auven Therapeutics (previously known as Celtic Therapeutics). ADCT has a strategic collaboration with Spirogen Ltd, also an Auven Therapeutics’ portfolio company, for the supply of warhead chemistries and R&D services. It operates a virtual business model based in Lausanne, Switzerland.

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast, lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linkers chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune.

ADCT was launched in 2012 with a $50m commitment from private equity firm Auven Therapeutics, which retained majority ownership. In 2013 AstraZeneca took an equity stake in the Company, investing $20 million. The Company is located in Lausanne, Switzerland with the scientific team leading the drug development programs is based in laboratories at Queen Mary Bioenterprises Innovation Centre, London, UK.

About pyrrolobenzodiazepine (PBD) warhead technology

 

PBDs have been shown by researchers at a number of pharmaceutical companies to be dramatically more efficacious than first generation warhead chemistries in a wide range of preclinical models of different tumor types. In 2013 ADCT and Spirogen published data showing that the Herceptin monoclonal antibody conjugated with a PBD warhead yields a large proportion of Complete Responses in HER2-positive cancer models, including low HER2-expressers. In contrast, the first generation ADC-targeting HER2, now approved for refractory HER2-positive breast cancer, only slows tumor cell growth in these models although significantly longer than stand-alone Herceptin. Seattle Genetics announced the filing of an IND on its first PBD-warheaded ADC, developed under a license from Spirogen, in 2013, and recently stated they intended to file an IND on a second PBD-warheaded ADC this year.

About Auven Therapeutics (www.auventx.com)

Auven Therapeutics is a global private equity firm that acquires and pursues accelerated development of breakthrough therapeutic drugs prior to licensing them to commercial partners. Auven’s in-house team of senior pharmaceutical development executives establish the clinical, regulatory, manufacturing and commercial strategies for all its products and oversees their execution. Auven was founded in 2007 by Stephen Evans-Freke and Dr. Peter B. Corr, and maintains operations in Lausanne, London, New York, Bermuda, and the U.S. Virgin Islands.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics

5 November 2013

LAUSANNE, SWITZERLAND and SOUTH SAN FRANCISCO, CA, USA – November 5 2013

– ADC Therapeutics Sarl (‘ADC Therapeutics’), a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), and Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

Under the agreement, ADC Therapeutics plans to initiate preclinical research and development of antibody-drug conjugates using the antibodies licensed from Five Prime immediately, adding to ADC Therapeutics’ portfolio of proprietary ADC programs. ADC Therapeutics’ unique platform combines monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As ADC Therapeutics’ PBD-based chemistries do not distort the structure of the DNA they give the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market.

Dr. Peter B. Corr, Chairman of ADC Therapeutics and Managing General Partner of Auven Therapeutics, said: “We believe that ADCs offer a great opportunity to develop next generation oncology drugs that are more efficacious and with less side effects. The partnership with Five Prime further extends our exciting development portfolio of novel ADCs and we look forward to rapidly progressing the development plans.”

“ADC Therapeutics is a leader in developing proprietary antibody-drug conjugates targeting major cancers such as breast, lung, prostate, renal and blood,” said Lewis T. “Rusty” Williams, M.D., Ph.D., President and CEO of Five Prime. “We believe that antibodies directed toward this protein target, which is found on a variety of tumor types, will be most efficacious when armed with a cytotoxic drug conjugate. This strategic license allows us to progress a program by leveraging Five Prime’s strength in the development of novel biologic products and ADCT’s complementary strength in arming antibodies for use in treating cancer.”

Financial terms were not disclosed and remain confidential.

 

- ENDS -

 

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics Sarl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADC Therapeutics has its head office in Lausanne, Switzerland and through subsidiaries has its R&D laboratories in London, UK, its clinical development team in New Jersey, USA, and its manufacturing team based in San Francisco, USA. With its industry leading management team and board of directors, ADC Therapeutics is a leader in the development of PBD-based ADCs.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

AstraZeneca's MedImmune Acquires Spirogen, Invests in ADC Therapeutics

15 October 2013

Auven Therapeutics Announces AstraZeneca’s MedImmune Acquires Antibody-Drug Conjugate Company Spirogen and Invests in ADC Therapeutics

Both Auven Therapeutics Portfolio Companies

MedImmune acquires 100% of Spirogen for $200 million in cash and deferred consideration of up to $240 million

MedImmune and ADC Therapeutics enter into a collaboration agreement for two of ADC Therapeutics’ oncology programs

MedImmune pays $20 million for an equity investment in ADC Therapeutics matched by a $20 million additional investment from Auven Therapeutics

MedImmune’s Executive Vice President, Dr. Bahija Jallal, joins ADC Therapeutics’ board

LAUSANNE, SWITZERLAND, LONDON, UK, ST THOMAS, U.S. VIRGIN ISLANDS, AND NEW YORK, USA, October 15, 2013

Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs addressing unmet medical needs, today announced that its strategic investment in the antibody-drug conjugate (ADC) field has been validated by the sale of its platform technology portfolio Company Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca.

MedImmune has also entered into a collaboration agreement with portfolio Company ADC Therapeutics to jointly develop two of ADC Therapeutics antibody-drug conjugate programs in preclinical development. MedImmune and Auven will also make an equity investment in ADC Therapeutics.

ADCs are a clinically-validated cancer drug technology that offers both high potency and selective targeting of cancer cells. Spirogen’s proprietary pyrrolobenzodiazepine (PBD) technology attaches highly potent cytotoxic agents, or ‘warheads’ to specific cancer-targeting antibodies using biodegradable ‘linkers’. This targeting optimises the delivery of the cancer drug to the tumour cells only and provides the greatest degree of tumour killing while minimising the toxicity to the patient.

Dr. Peter B. Corr, co-founder and Managing General Partner of Auven and Chairman of ADC Therapeutics said: “We anticipate that our work in the ADC field will be a major driver of value in our fund. We believe that ADCs are one of the most interesting and important areas we have worked on in our careers. The combination of tumor-specific antibodies with highly potent cytotoxic warheads will be game changing in the oncology field.”

Spirogen sale

MedImmune will acquire 100 per cent of the shares of Spirogen for an initial consideration of $200 million and deferred consideration of up to $240 million based on reaching predetermined development milestones. Existing out-licensing agreements remain in place, milestones and royalty rights under which have been transferred into a holding company 75% owned by Auven.

Commenting on the sale, Spirogen CEO Dr. Chris Martin said: “This deal reflects the very significant progress made by our scientists, most notably over the last two years, as we have applied our warhead and linker technologies to the development of highly potent and specific ADCs. We believe that PBD-armed antibody-drug conjugates will emerge as a critical component in the next generation of cancer biologics with the potential to make a difference for oncologists and their patients. We look forward to combining our world class capabilities in this area with MedImmune’s ability to develop this exciting class of oncology drugs.”

Following Auven’s investment in Spirogen, the Company has expanded and made major technical advances toward optimizing the stability and therapeutic window of PBD-warheaded ADCs, working closely with its collaborators including ADC Therapeutics.

Stephen Evans-Freke, co-founder and Managing General Partner of Auven and Chairman of Spirogen commented: “While our business strategy for Spirogen had been to license its ADC warhead technology to multiple industry partners, an unsolicited approach by an unrelated party to this deal to acquire the Company caused us to explore with Lazard the potential for enhanced value realization through an outright sale. While we had interest from various parties, MedImmune stood out as an ideal partner. We were very pleased with the outcome.”

ADC Therapeutics agreements

The collaboration agreement entered into between MedImmune and ADC Therapeutics will include an upfront payment with predetermined development milestones for two programs from a defined list. The parties have a cost- and profit- sharing arrangement with MedImmune representing the majority share. ADC Therapeutics retains the option to co-promote one of the two products in the US.

MedImmune will also pay $20 million for an equity investment in ADC Therapeutics matched by a $20 million additional investment from Auven Therapeutics on the same terms.

Michael Forer, CEO of ADC Therapeutics and a Managing Director of Auven, said: “The $40 million equity investment in ADC Therapeutics combined with the economic terms of the collaboration agreement with MedImmune ensure that the Company is now well-funded to achieve its mission. Outside of our arrangement with MedImmune, we aim for ADC Therapeutics to have multiple proprietary products in clinical development within two years and to achieve clinical proof-of-concept by 2017.”

Dr. Bahija Jallal, Executive Vice President of MedImmune said, “Antibody-drug conjugates are ground-breaking technologies with the potential for directly targeting many types of cancer tumours while safeguarding healthy cells. The cutting-edge technologies developed by Spirogen and ADC Therapeutics complement MedImmune’s innovative antibody engineering capabilities, enabling us to accelerate antibody-drug conjugates into the clinic” she said.

“MedImmune is a natural partner for us given its depth of antibody expertise, its oncology focus and the commitment of its leadership to bring a number of break-through cancer therapeutics incorporating this exciting technology to patients as rapidly as possible. We are also excited to have Dr. Bahija Jallal with all her expertise in this area join the Board of ADC Therapeutics,” concluded Mr Evans-Freke and Dr. Corr.

Lazard Freres & Co. LLC acted as lead advisor to Spirogen and ADC Therapeutics and Arnold & Porter LLP served as legal counsel.

 

- ENDS -

 

About ADC Therapeutics (www.adctherapeutics.com)

ADC Therapeutics Sarl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune. Its lead program, ADCT-301 for lymphoma entered Phase I in mid 2015.

ADC Therapeutics has its head office in Lausanne, Switzerland and through subsidiaries has its R&D laboratories in London, UK, its clinical development team in New Jersey, USA, and its manufacturing team based in San Francisco, USA. With its industry leading management team and board of directors, ADC Therapeutics is a leader in the development of PBD-based ADCs.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

15 July 2013

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

Lausanne, Switzerland and New York, US – 15 July 2013 − ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates (‘ADCs’), and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

PSMA is a cell-surface antigen on prostate cancer cells, and PSMA levels correlate directly with an aggressive, metastasizing phenotype. The characteristics of PSMA – its cancer specificity, presence in 95% of prostate cancers, high level of expression, and rapid internalization – make it an ideal ADC target.

ADC Therapeutics plans to initiate pre-IND development of a PSMA-specific ADC immediately, adding to ADC Therapeutics’ portfolio of proprietary ADC programs. Its unique platform combines monoclonal antibodies specific to particular types of tumor cells, in this case PSMA, with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As ADC Therapeutics PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market.

Dr Neil H. Bander, Director of Urological Oncology Research at Weill Cornell Medical College from where the anti-PSMA antibody was licensed, said: “We have direct experience with virtually every antibody-drug conjugate platform currently available; none have produced the level of efficacy we have seen with ADC Therapeutics’ PBD warheads - in vivo efficacy data from their PSMA-targeted ADC drug candidate are truly exciting, and we are excited to see this potentially breakthrough therapy translated into a clinic program as soon as possible.”

Dr. Peter B. Corr, Chairman of ADC Therapeutics and Managing General Partner of Auven Therapeutics, said: “Having the technology platform to develop novel ADCs against important cancer targets and transform healthcare outcomes for patients is a critical part of what we are building at ADC Therapeutics. We are pleased to have established this exclusive relationship with the outstanding team in Dr. Bander’s laboratories at Weill-Cornell.”

Financial terms were not disclosed and remain confidential.

About ADC Therapeutics Sarl

 

ADC Therapeutics (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As its PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market. The company was formed in 2012 with a $50m commitment from private equity firm Auven Therapeutics (previously known as Celtic Therapeutics). ADCT has a strategic collaboration with Spirogen Ltd, also an Auven Therapeutics’ portfolio company, for the supply of warhead chemistries and R&D services. It operates a virtual business model based in Lausanne, Switzerland.

For further information please see: www.adctherapeutics.com

 

About Auven Therapeutics

 

Auven Therapeutics was founded by Stephen Evans-Freke and Dr. Peter B Corr in 2007 with an innovative investment strategy - while it is structured as a private equity fund, it also operates as a drug development company. Auven Therapeutics has a portfolio of biologic and small molecule therapeutic candidates for a range of therapeutic indications including cancer, ophthalmic conditions, women’s health and orphan diseases. Auven manages its drug development activities from its bases in Lausanne, Switzerland, New York, USA and Hamilton, Bermuda. Auven Therapeutics Management L.L.L.P., based in the U.S. Virgin Islands, serves as its Investment Advisor.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead

17 June 2013

  • Antibody-drug conjugate (ADC) to be developed for cancer
  • Combines strength of HuMax®-TAC with next generation PBD-based warhead technology
  • 50:50 partnership

Copenhagen, Denmark and Lausanne, Switzerland; 17 June 2013 – Genmab A/S (OMX: GEN) and ADC Therapeutics, announced today an agreement to develop a new antibody-drug conjugate (ADC) product combining Genmab’s HuMax-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. The Companies have been conducting in vitro and in vivo studies since 2012 to investigate different warhead and linker combinations with HuMax-TAC, and now have the product ready for pre-IND preclinical development. The product will be developed for multiple cancer indications.

Genmab and ADC Therapeutics will each initially have an equal share in the product. In the first instance, ADC Therapeutics will lead and fund preclinical development. Prior to the submission of an application to conduct clinical studies in patients (IND filing), Genmab may elect to retain equal ownership of the product. Genmab will not incur any development costs prior to the IND filing decision and Genmab will maintain a minimum 25% ownership stake in the product as it moves into clinical development. No other financial terms were disclosed.

“We believe our unique HuMax-TAC antibody has optimal characteristics for creation of an ultra-potent antibody-drug conjugate when used in combination with ADC Therapeutics’ novel PBD-based warhead and linker technology, which employs an emerging class of highly potent anticancer agents. This agreement is another example of a win-win partnership combining Genmab’s state-of-the-art antibody development expertise with the latest advance in antibody-payload technology,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Dr. Peter B, Corr, Chairman of ADC Therapeutics said: “We are very excited to be developing an ADC with our new partner Genmab and incorporating our next generation PBD-based toxins into this product. Our warhead payload technology enjoys exquisite potency, optimised conjugation and pharmaceutical properties that maintain activity in highly resistant cancers. Our pre-clinical data for this product indicate the potential for curative efficacy in highly resistant populations at low ADC doses of this product in several oncology indications, an area with critical unmet needs”.

This agreement does not affect Genmab’s 2013 financial guidance.

About HuMax-TAC

 

HuMax-TAC is a high-affinity fully human antibody targeting CD25, a therapeutic target with strong clinical validation. CD25 is expressed on a variety of hematological tumors and shows limited expression on normal tissues, which makes it a very attractive target for antibody-payload approaches. With HuMax-TAC-ADC, we aim to develop a first-in-class antibody-drug conjugate for the potential treatment of CD25-expressing lymphomas and leukemias.

About PBD Warheads & Linkers

 

ADCs developed using ADC Therapeutics’ technology combine monoclonal antibodies specific to particular tumor targets with highly potent pyrrolobenzodiazepine (PBD) based warheads developed by ADC Therapeutic’s partner Spirogen Limited. These PBD warheads are joined to antibodies by linkers that release the PBD warhead in the targeted cancer cells. This technology has attracted the attention of other biotechnology companies such as Genentech and Seattle Genetics.

About ADC Therapeutics

 

ADC Therapeutics (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As its PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market. The company was formed in 2012 with a $50m commitment from private equity firm Auven Therapeutics (previously known as Celtic Therapeutics). ADCT has a strategic collaboration with Spirogen Ltd, also an Auven Therapeutics’ portfolio company, for the supply of warhead chemistries and R&D services. It operates a virtual business model based in Lausanne, Switzerland.

 

About Auven Therapeutics

 

ADC Therapeutics sarl (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. As its PBD-based chemistries do not distort the structure of the DNA it gives the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market. The company was formed in 2012 with a $50m commitment from private equity firm Auven Therapeutics (previously known as Celtic Therapeutics). ADCT has a strategic collaboration with Spirogen Ltd, also an Auven Therapeutics’ portfolio company, for the supply of warhead chemistries and R&D services. It operates a virtual business model based in Lausanne, Switzerland.

About Genmab A/S

 

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company’s first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab’s validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit

www.genmab.com.

Contact Genmab:

 

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication

T: +45 33 44 77 20; M: +45 25 12 62 60;

r.gravesen@genmab.com

Contact ADC Therapeutics:

 

Sue Charles/Stefanie Bacher/Gemma Howe, College Hill Life Sciences (PR Agency for ADC Therapeutics

T: +44 (0) 20 7457 202;

E: adct@collegehill.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; DuoBody®, HexaBodyTM and UniBody®. Arzerra® is a trademark of GlaxoSmithKline.


For more information please contact:

Instinctif Partners

Sue Charles / Gemma Howe

T: +44 (0)20 7866 7860

adctherapeutics@instinctif.com

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

6 July 2012

London and Lausanne, 6 July 2012 - Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT)* announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries.

ADCs are an exciting and clinically important class of oncology drugs as they combine the specificity of antibodies with novel ‘warhead’ chemistries. The antibody component selectively targets the cancer cells to deliver tumour-destroying chemicals which are internalised into the cancer cell while avoiding damage to healthy tissue. Once inside the cancer cell, the linker degrades and the active toxin is released, binding to the cell’s DNA and killing the cancer cell. ADCT’s toxic chemicals interact with DNA without disrupting the double helix structure which avoids triggering DNA repair processes – with the prospect that this will prevent drug resistance.

ADCT’s warheads are based on proprietary pyrrolobenzodiazepines (PBDs) technology developed by London-based Spirogen Limited. In March 2012, ADCT and Spirogen announced their partnership to develop proprietary ADC products. CRT holds the intellectual property (IP) rights to a range of tumour-targeting agents** developed by Cancer Research UK scientists.

ADCT will initially fund preclinical studies for the new ADCs in a range of cancer models in laboratories at Queen Mary, University of London, University College London and King’s College London. Deal terms are not disclosed, nor the cancer targets.

Dr Chris Martin, ADCT’s collaboration manager and CEO of Spirogen Limited, said: “We are very excited to see our potent PBD-based warheads combined with CRT’s leading tumour-targeting antibodies and peptides. Together we are committed to faster and more efficient drug development, and have already commenced our preclinical work for these exciting programs. We believe this provides a very promising and rapid route to develop novel ADCs for cancer therapy and are very much looking forward to working in partnership with CRT.”

Dr Phil L’Huillier, CRT’s director of business management, said: “There’s very promising evidence that ADCs could be an important new way to treat cancer. This is a particularly exciting time in this field, following the recent approval by the FDA for the first use of an ADC to treat lymphoma. This unique collaboration marries ADCT’s targeted portfolio with CRT’s access to world-class cancer research supported by £334 million each year. We hope the collaboration will identify a range of ADCs that can be taken forward for development into innovative new ways to treat cancer and save lives.”

News

5 December 2015

ADC Therapeutics Announces Positive Pre-clinical Results for Two of its Novel ADCs at the American Society of Hematology Conference

Read more


4 December 2015

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for its Second Novel Antibody Conjugate ADCT-402 against Lymphomas and Leukemia

Read more


28 September 2015

ADC Therapeutics Announces Expanded Board with Appointment of Highly Experienced Non-Executive Directors

Read more


2 September 2015

ADC Therapeutics Secures $80m Financing to Progress its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology

Read more


22 June 2015

ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

Read more


19 April 2015

ADC Therapeutics Presented Positive Pre-clinical Activity of its Novel Anti-CD22 Antibody-Drug Conjugate at the American Association for Cancer Research (AACR) Annual Meeting

Read more


16 March 2015

ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas

Read more


30 September 2014

ADC Therapeutics Expands Team

Read more


19 May 2014

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

Read more


5 November 2013

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics

Read more


15 October 2013

AstraZeneca's MedImmune Acquires Spirogen, Invests in ADC Therapeutics

Read more


15 July 2013

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

Read more


17 June 2013

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead

Read more


6 July 2012

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

Read more


News

2015

5 December 2015

ADC Therapeutics Announces Positive Pre-clinical Results for Two of its Novel ADCs at the American Society of Hematology Conference

Read more


4 December 2015

ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for its Second Novel Antibody Conjugate ADCT-402 against Lymphomas and Leukemia

Read more


28 September 2015

ADC Therapeutics Announces Expanded Board with Appointment of Highly Experienced Non-Executive Directors

Read more


2 September 2015

ADC Therapeutics Secures $80m Financing to Progress its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology

Read more


22 June 2015

ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

Read more


19 April 2015

ADC Terapeutics Presented Positive Pre-clinical Activity of its Novel Anti-CD22 Antibody-Drug Conjugate at the American Association for Cancer Research (AACR) Annual Meeting

Read more


16 March 2015

ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas

Read more


2014

30 September 2014

ADC Therapeutics Expands Team

Read more


19 May 2014

ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

Read more


2013

5 November 2013

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics

Read more


15 October 2013

AstraZeneca's MedImmune Acquires Spirogen, Invests in ADC Therapeutics

Read more


15 July 2013

ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

Read more


17 June 2013

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead

Read more


2012

6 July 2012

Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

Read more


A diversified pipeline with ADCs
for treatment of solid and hematological cancers

ADC Therapeutics has a diversified pipeline of ADCs that utilizes the PBD payload technology for the treatment of a variety of hematological and solid cancers with high unmet medical need.



(a) : ADCT-401 is partnered with Medimmune/AstraZeneca.



Clinical Trials

ADCT-301 is being developed for the treatment of CD25-expressing lymphoma and leukemia. ADCT-301 is an antibody drug conjugate (ADC) composed of the human monoclonal antibody HuMax®-TAC (licensed from Genmab A/S), directed against human CD25, conjugated to a potent pyrrolobenzodiazepine (PBD) dimer toxin. We have reported preclinical data demonstrating potent antitumor activity of ADCT-301 against CD25-expressing haematological tumors1,2

For lymphoma, CD25 expression has been demonstrated in Hodgkin’s Lymphoma3,4 and many types of Non-Hodgkin’s lymphoma including Follicular Lymphoma4 and Diffuse Large B-cell Lymphoma5. To read more about Hodgkin and Non-Hodgkin Lymphoma, click here and here, respectively. A Phase I clinical trial with ADCT-301 in patients with relapsed or refractory HL and NHL (Study NCT02432235) is open for enrollment and ongoing.

For acute myeloid leukemia, CD25 expression has been demonstrated in newly diagnosed and relapsed AML6, and in late-stage myelodysplastic syndrome related AML. Also, CD25 expression in AML correlates with poor prognosis7. A Phase I clinical trial with ADCT-301 in patients with AML (Study NCT02588092) is open for enrollment and ongoing. To read more about AML, click here.

References

  • Flynn, M., et al., Pre-Clinical Activity of ADCT-301, a Novel Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Blood, 2014. 124(21): p. 4491.
  • Flynn, M., et al., Mechanistic and Pharmacodynamic studies of ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies Blood, 2015. 126(23).
  • Schnell R, V.E., Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A., Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk Lymphoma, 1998. 30(5-6): p. 525-57.
  • Fujiwara, S.I., et al., Clinical features of de novo CD25-positive follicular lymphoma. Leuk Lymphoma, 2013.
  • Fujiwara, S., et al., Clinical features of de novo CD25(+) diffuse large B-cell lymphoma. Hematology, 2013. 18(1): p. 14-9.
  • Gonen, M., et al., CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood, 2012. 120(11): p. 2297-306.
  • Miltiades, P., et al., Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. Blood Cancer J, 2014. 4: p. e187.

ADCT-402 is being developed for the treatment of CD19-expressing non-Hodgkin’s lymphoma and B-cell leukemia. ADCT-402 is composed of a humanized antibody directed against human CD19, conjugated to a potent PBD dimer toxin. We have reported preclinical data demonstrating potent antitumor activity of ADCT-402 against CD19-expressing B-cell malignancies1

CD19 expression has been demonstrated in many types of Non-Hodgkin lymphoma2 including Burkitt’s Lymphoma, Follicular Lymphoma and Diffuse Large B-cell Lymphoma. To read more Non-Hodgkin about Lymphoma, click here. A Phase I clinical trial with ADCT-402 in patients with relapsed or refractory NHL is scheduled to start early 2016.

For leukemia, CD19 expression has been demonstrated in newly diagnosed and relapsed pre B-cell acute lymphoblastic leukemia (pre BALL), BALL and hairy cell leukemia (HCL)3. A Phase I clinical trial with ADCT-402 in patients with B-ALL is scheduled to start early 2016. To read more about ALL, click here.

References

  • Zammarchi, F., et al., Pre-clinical Development of ADCT-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-cell Malignancies. Blood, 2015. 126(23).
  • Anderson, K.C., et al., Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood, 1984. 63(6): p. 1424-33.
  • Scheuermann, R.H. and E. Racila, CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma, 1995. 18(5-6): p. 385-97.

Technology

ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of hematological and solid cancers. Our ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface tumor antigens with the latest generation of a novel class of highly potent pyrrolobenzodiazepine (PBD) dimer toxins1.

PBD dimers have a different mode of action compared to payloads such as maytansinoids and auristatins which have been commonly used in other ADCs. Following binding of the antibody to a specific tumor cell surface antigen and internalization of the ADC, the cytotoxic PBD dimer is released inside the cells where it binds in the minor groove of DNA and forms potent cytotoxic DNA interstrand cross-links. The cross-links formed by the PBD dimer block cell division and kill the cancer cell (click this here to see a diagram of this mechanism of action). Importantly, PBD dimers are non-distorting of the DNA structure, making them invisible to repair mechanisms and therefore allow the cross-links to persist within the DNA and so result in a long duration of activity even in hard to treat tumors.

ADC Therapeutics believes the unique mode of action of PBD dimers, together with their ‘stealth-like’ properties, will result in ADC products with superior efficacy and reduced drug resistance profile.

ADC Therapeutics has access to PBD dimers and linkers chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune).

References

1. Hartley, J.A., The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs, 2011. 20(6): p. 733-44.

ADC Therapeutics has completed numerous corporate partnerships, including:

 

 

To discuss a potential partnership opportunity with
ADC Therapeutics please contact: info@adctherapeutics.com

Peter B. Corr, Ph.D.

Chairman of the Board

Dr. Peter B. Corr is the Chairman of the Board of ADC Therapeutics and Co-Founder and Managing General Partner of Auven Therapeutics Management. He retired from Pfizer Inc. in December 2006 where he was Senior Vice President for Science and Technology.

Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development; and Senior Vice President, Discovery Research, at Monsanto/Searle and then as President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis. He spent 18 years at Washington University in St. Louis as Professor, Department of Medicine (Cardiology) and Department of Pharmacology and Molecular Biology.

He has held a number of Chairmanships including the Science & Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA); the PhRMA Foundation Board of Directors; and the Hever Group.

Dr. Corr is a past Governor and Chair of the New York Academy of Sciences, a member of the Board of Regents of Georgetown University and a Chairman of the Board of the International Partnership for Microbicides and of the Critical Path Institute. Dr. Corr also served on the boards of Furiex Pharmaceuticals, Inc., Global Edit, Inc., and the African Leadership Congress.



Jay Feingold, M.D., Ph.D.

Senior Vice President, Chief Medical Officer and Head of Oncology

Dr. Jay Feingold is Senior Vice President, Chief Medical Officer and Head of Oncology Clinical Development of ADC Therapeutics.

Dr. Feingold has shared his career between the academic medicine and the pharmaceutical industry.  Before joining ADC Therapeutics, Dr. Feingold was Vice President of US Medical Affairs and Chairman of the Global Medical Affairs Oversight Committee at Daiichi Sankyo.

Dr. Feingold was previously Vice President of Global Oncology Clinical Development and Global Therapy Area Director of Oncology at Wyeth. Before joining Wyeth, Dr. Feingold was a member of the Departments of Medicine and Pediatrics and Associate Director of the Bone Marrow Transplant Program at the University of Connecticut overseeing the Alternative Donor and Pediatric Transplant Programs.

Dr. Feingold received his M.D. and Ph.D. degrees from the Albert Einstein College of Medicine and trained in Pediatrics and Pediatric Hematology and Oncology at the UCLA Center for the Health Sciences.



Simon Chivers, Ph.D.

Head of Toxicology

Simon Chivers is Head of Toxicology at ADC Therapeutics.

Dr. Chivers has extensive experience in the pharmaceutical and biotech industry, specializing in the safety assessment, development of protein and antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. Chivers spent six years with Novartis, most recently as Executive Director and Global Head of Biologics Safety Assessment, responsible for the non-clinical development of the Novartis biologics portfolio. Prior to Novartis he was a senior non-clinical safety assessment expert at AstraZeneca, working closely with MedImmune.  In addition, Dr. Chivers has held leadership roles at Syngenta BioPharma, Syngenta CTL and Quintiles.

Dr. Chivers has a degree in Pharmacology from University College London and a Ph.D. in Applied Pharmacology from Imperial College London.



Stephen Evans-Freke

Non Executive Director

Stephen Evans-Freke is Non Executive Director of ADC Therapeutics and Co-Founder and Managing General Partner of Auven Therapeutics.  Mr. Evans-Freke has been associated with the biotechnology industry for over 35 years as an investment banker, asset manager, entrepreneur, company CEO, and venture capitalist. During the 1980s, he was lead investment banker to Genentech, AMGEN, Centocor, and a number of other leading biotech companies. During this period, Mr. Evans-Freke served as President of PaineWebber Development Corporation and later a member of PaineWebber Inc.'s Board of Directors.

In 1990 Mr. Evans-Freke founded Selectide Corporation, where he served as Chairman until its sale to Hoechst in 1994. In 1991 he founded SUGEN, a drug discovery company, and served as Chairman and Chief Executive Officer through it’s IPO in 1995 until it’s sale to Pharmacia in 1999. Mr. Evans-Freke was also a co-founder of Fibrogen, Inc., Royalty Pharma AG, and CIBUS Global LLC, serving as Chairman of the latter until 2013.

Mr. Evans-Freke serves on the 800th Anniversary Appeal Board of Cambridge University, from which he holds a Degree in Law, and also on the Board of the Christopher and Dana Reeve Foundation.



Michael Forer

Executive Vice President and Vice Chairman

Michael Forer is Vice Chairman of ADC Therapeutics having served as its Chief Executive Officer from formation to June 2015, and is also Executive Vice President focused on its public markets capital strategy, business and finance activities. Mr. Forer is also a Managing Director of Auven Therapeutics.

Prior to joining ADC Therapeutics and Auven, Mr. Forer co-founded Rosetta Capital Limited, a London private equity firm focused on the life science sector. Prior to Rosetta, Mr. Forer was an investment manager at Rothschild Asset Management where he was responsible for making and managing private equity investments in North America and Europe in the life science sector. Mr. Forer has also been an active corporate finance and M&A advisor to private and public life science based clients.

Mr. Forer has a law degree from the University of British Columbia (1990), a diploma in International Business from the University of Copenhagen (1987), and a bachelor of economics from the University of Western Ontario (1986). Mr. Forer is called to the Bar for the Law Society of Upper Canada.



Maria Cincotta

Executive Director of Clinical Operations

Maria Cincotta is Executive Director of Clinical Operations at ADC Therapeutics.

Ms. Cincotta has extensive experience in managing and leading clinical programs within the pharmaceutical industry, and was formerly a clinical research and operations consultant focused in oncology for both biotech and pharmaceutical companies.  Prior to this, she was a Global Clinical Program Leader in the oncology division at Wyeth, with responsibility for early and late stage assets, managing the Torisel™ (temsirolimus) clinical research program through global product registration for renal cell carcinoma and mantle cell lymphoma.

Ms. Cincotta received her undergraduate degree from the University of Massachusetts, and a MS in Clinical Investigation from the MGH Institute of Health Professions in Boston Massachusetts.



Michael Forer

Executive Vice President and Vice Chairman, Director

Michael Forer is Vice Chairman and Director of ADC Therapeutics having served as its Chief Executive Officer from formation to June 2015, and is also Executive Vice President focused on its public markets capital strategy, business and finance activities.  Mr. Forer is also a Managing Director of Auven Therapeutics.

Prior to joining ADC Therapeutics and Auven, Mr. Forer co-founded Rosetta Capital Limited, a London private equity firm focused on the life science sector.  Prior to Rosetta, Mr. Forer was an investment manager at Rothschild Asset Management where he was responsible for making and managing private equity investments in North America and Europe in the life science sector.  Mr. Forer has also been an active corporate finance and M&A advisor to private and public life science based clients.

Mr. Forer has a law degree from the University of British Columbia, a diploma in International Business from the University of Copenhagen, and a bachelor of economics from the University of Western Ontario. Mr. Forer is called to the Bar for the Law Society of Upper Canada.



Dulce Gonçalves

General Counsel and Corporate Secretary

Dulce Gonçalves is General Counsel and Corporate Secretary of ADC Therapeutics.

Ms. Gonçalves made the vast majority of her career in the pharmaceutical industry and brings broad expertise in all fields of health science, from research and development activities, to technical operations and manufacturing, regulatory affairs, medical and marketing activities, business development & licensing, healthcare compliance, and launch and commercialization of pharmaceutical products.

Ms. Gonçalves was most recently Senior Legal Counsel, Global Product Strategy and Commercialization, at Novartis.  Prior to her role at Novartis, Ms. Gonçalves served as Senior Legal Counsel at Celgene International and UCB SA. She was also previously International Legal Counsel at France Telecom (now Orange) International Networks and Carriers division.

Ms. Gonçalves holds a Masters degree in Business Law and Foreign Languages from the University Pierre Mendès France of Grenoble, France and a LLM in International Business Law from the University of Bourgogne, Dijon, France.



David Ellis, Ph.D.

Head of Global Regulatory Affairs

Dr. David Ellis is Head of Global Regulatory Affairs at ADC Therapeutics.

Dr. Ellis has very extensive experience in global regulatory affairs, holding positions in both Europe and the USA. Dr. Ellis is experienced in the global development and registration of small molecule and biologic therapies.

Prior to joining ADC Therapeutics, Dr. Ellis was Vice President of Regulatory Affairs for Aptalis Pharma US. Prior to this Dr. Ellis held positions at Cephalon and previously Wyeth Pharmaceuticals, where he was Global Therapeutic Area Head for Oncology & Hemophilia, and Inflammation & Immunology.

Dr. Ellis is a graduate of the University of Nottingham, UK, where he received his PhD in Molecular Biology.



Bahija Jallal, Ph.D.

Non Executive Director

Dr. Bahija Jallal is Non Executive Director of ADC Therapeutics, as well as Executive Vice President of AstraZeneca and Head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK.  She is a member of the senior executive team at AstraZeneca reporting to the CEO. Dr. Jallal joined MedImmune in March 2006.

Dr. Jallal is a member of the Board of Trustees of the Johns Hopkins University.  She is also a member of the Board of Directors of the University of Maryland Health Sciences Research Park Corporation, a non-profit organization that manages biomedical research development at the BioPark.

Dr. Jallal has authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory board member of the Healthcare Business Women’s Association. She was recognized as one of FierceBiotech’s 2011 Women in Biotech and in 2012, she received Washington Business Journal’s Women Who Mean Business award.

Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as Vice President, Drug Assessment and Development, and successfully established the company’s translational medicine group; and previously at Sugen, Inc. where she held positions of increasing responsibility leading to Senior Director, Research.

Dr. Jallal received a master’s degree in biology from the Université de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.



Stéphane Henchoz

Finance Director

Stéphane Henchoz is Finance Director at ADC Therapeutics.

Mr. Henchoz spent all his career in finance in the pharmaceutical industry.

Prior to joining ADC Therapeutics, Mr. Henchoz held senior leadership roles at Merck Serono most recently as Controlling Manager for the Research and Development Function. While at Merck Serono, he also served in various finance functions, including Financial Controller for the IT Function in Geneva, Associate Manager at the Corporate Strategic Management Department in Geneva, and Regional Financial Analyst for the Latin America Region in Uruguay.

Mr. Henchoz has a Bachelor in Economics and Finance from the HEG (Haute Ecole de Gestion) in Geneva.



Prof. John Hartley

Advisor

Prof. John Hartley is advisor to ADC Therapeutics and Professor of Cancer Studies at UCL. He was one of the founders of Spirogen.

Prof. Hartley is also Director of the Cancer Research UK Drug-DNA Interactions Research Group and Co-Lead of the UCL Experimental Cancer Medicine Centre. Prior to joining UCL he was a Visiting Fellow at the National Cancer Institute, USA and an Alberta Heritage Research Fellow at the University of Alberta, Canada.

John has a B.Sc. in Biochemistry and a Ph.D. in Experimental Chemotherapy from the University of Manchester. He has over 280 publications in the fields of molecular and clinical pharmacology, DNA damage and repair, drug design and development, and cancer therapeutics. He is a Fellow of both the Royal Societies of Biology and Chemistry and is an Honorary Member of the Royal College of Radiologists. He is also Chair of the Protocol Safely and Review Board of Cancer Research UK.



Chris Martin

Chief Executive Officer

Dr. Chris Martin is Chief Executive Officer and Director of ADC Therapeutics. He played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding.

Previously Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca, in October 2013, at which point he became both a member of MedImmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group.

Prior to the acquisition by AstraZeneca MedImmune, Dr. Martin led numerous Spirogen collaboration transactions, including agreements with two of the leading industry players in the antibody drug conjugate area, Genentech and Seattle Genetics.

He is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow.



Chris Martin

Chief Executive Officer

Dr. Chris Martin is Chief Executive Officer and Director of ADC Therapeutics. He played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding.

Previously Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca, in October 2013, at which point he became both a member of MedImmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group.

Prior to the acquisition by AstraZeneca MedImmune, Dr. Martin led numerous Spirogen collaboration transactions, including agreements with two of the leading industry players in the antibody drug conjugate area, Genentech and Seattle Genetics.

He is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow.



Karin Havenith, Ph.D.

Principal Bio Analytical Scientist

Dr. Karin Havenith is Principal BioAnalytical Scientist at ADC Therapeutics.

Dr. Havenith is experienced in the biotech industry, specialized in the development and validation of non-clinical and clinical bio-analytical assays, as well as CMC related bio-analytical assays for antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. Havenith was at Crucell Holland BV (Johnson & Johnson Company) as Biologicals Assay Manager for antibody-based therapeutics, and prior to Crucell she worked for more than seven years at Genmab, as Principal Scientist on cancer-target related antibody-based therapeutics. Prior to the biotech industry, Dr. Havenith spent more than 15 years in  academia at TNO Prevention & Health in Leiden, NL, St. Jude Children’s Hospital, Memphis TN, US, and Vrije University, Amsterdam, NL.

Dr. Havenith graduated with her M.Sc. in Animal Husbandry from the University of Wageningen, NL, and obtained a Ph.D. in Cell Biology & Immunology from the Vrije University, Amsterdam, NL.



Jacques Theurillat

Non Executive Director

As an independent Non Executive Director, Mr. Theurillat brings to the Board extensive experience in strategy development, finance and commercial operations.

He has been CEO of Ares Life Sciences AG and previously served as CEO and Chairman of Albea Pharmaceuticals AG.  He also had an extensive career at Serono, which spanned roles such as Chief Financial Officer, Deputy Chief Executive Officer and Senior Executive Vice President, Strategic Corporate Development.

Mr. Theurillat holds Bachelor of Law Degrees from Madrid University and Geneva University, a Master’s Degree in Finance from Centro Estudios Financieros, Madrid and a Swiss Federal Tax Expert Diploma.

Michael Mulkerrin, Ph.D.

Vice President, Head of CMC

Dr. Michael Mulkerrin is Vice President, Head of CMC (Chemistry Manufacturing and Control) of at ADC

Dr. Mulkerrin has extensive industry experience in biologics manufacturing. Prior to joining ADC Therapeutics, he held the position of Vice President, Process Development and Manufacturing at OncoMed Pharmaceuticals.

Prior to OncoMed, Dr. Mulkerrin was the Senior Director in Process Sciences at Amgen heading Analytical Biochemistry.   He also served in leadership positions in the development of therapeutic monoclonal antibody projects at Genentech and Abgenix. In 2010, Dr. Mulkerrin was elected to the USP Council of Experts, and is Chairman of the Biologics Monographs – Proteins Expert Committee.

Dr. Mulkerrin has a B.S. in Biochemistry from the University of Massachusetts, Amherst, and a Ph.D. in Biochemistry from the University of Georgia, Athens.



Shui He

Head of Biometrics

Dr. He is Head of Biometrics at ADC Therapeutics.

Dr. He has experience in the pharmaceutical and biotechnology industries.

Prior to joining ADC Therapeutics, Dr. He was Director of Biostatistics and Programming at Incyte Corporation, responsible for Jakafi ® (ruxolitinib), the first JAK inhibitor, submission for myelofibrosis,  and polycythemia vera. Prior to Incyte Corporation, Dr. He held positions at Sanofi, where he played an important role in the development of Jevtana ® (cabazitaxel), Taxotere ® (Docetaxel).

Dr. He is a graduate of the University of Pittsburgh, where he received his PhD in Biostatistics.



Barrie Ward, Ph.D.

Non Executive Director

Dr. Ward is Non Executive Director of ADC Therapeutics and brings a tremendous wealth of leadership skills and experiences to the Board of the company.

Dr. Ward is currently a member of the Board of BergenBio AS and of the Board of Supervisory Directors of Pharming Group N.V. He also served as Chief Executive Officer of KuDOS Pharmaceuticals Ltd. from 1999 until 2006 when the company was acquired by AstraZeneca, and Chief Executive Officer and Chairman of the Board of Directors of Virus Research Institute, Inc. He previously was Chairman of CellCentric Ltd and a member of the Board of Cancer Research Technology Ltd.

Earlier in his career, Dr. Ward worked in research for Glaxo Group Research, where he became Director of the Microbiology Division of Glaxo Research and Development Ltd.

Dr. Ward holds a B.Sc and a Ph.D. in microbial biochemistry from the University of Bath, England.



Patrick Van Berkel, Ph.D.

Senior Vice President Research & Development

Dr. van Berkel is Senior Vice President Research & Development of ADC Therapeutics.

Dr. van Berkel has conducted his entire career in the biotech industry, specializing in the development of antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. van Berkel spent more than nine years with Genmab as Director of Technology of Antibody Technology and most recently as Vice President of Chemistry, Manufacturing and Control Research & Development.

Dr. van Berkel has a chemistry degree from the University of Nijmegen, The Netherlands, and did his thesis at the University of Leiden, The Netherlands.



Richard Onyett

Vice President Business Development

Richard Onyett is Vice President Business Development at ADC Therapeutics.

Mr. Onyett has over 40 years of experience in the pharmaceutical and biotech industries.  Prior to joining ADC Therapeutics, Mr. Onyett was Commercial Director at Spirogen Limited responsible for business development with respect to licensing of PBD cytotoxin payload technology to major pharma and specialized biotech companies worldwide.

Prior to Spirogen, Mr. Onyett ran his own successful commercial development consultancy and subsequently served as Senior Vice President of Business or Corporate Development for a number of biotech companies based in the US, Europe and UK including KuDOS Pharmaceuticals where he was responsible for the BD strategy and activity that lead to the sale of KuDOS Pharmaceuticals to AstraZeneca in 2006.

Mr. Onyett began his career as International Product Manager with ICI Pharmaceuticals (now AstraZeneca) and subsequently as Director of Business Development for SmithKline and French (now GSK).

Mr. Onyett graduated with a B. Sc. (hons.) in Biological Sciences from the University of Nottingham, England and a M.Sc.in General Virology from the University of Birmingham, England.



Lisa Skelton, Ph.D.

Head of Project Management

Lisa Skelton is Head of Project Management at ADC Therapeutics.

Dr. Skelton spent most of her career in the pharmaceutical industry and has led numerous cross functional teams developing drugs, and in particular antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. Skelton was Associate Director, Program Management at Norgine Ltd.  Prior to Norgine, Dr. Skelton was Senior Project Manager at Amgen and at Antisoma Research Limited and Project Manager at UCB Celltech.

Dr. Skelton graduated with a B.Sc. (hons.) in Immunology from NESCOT and obtained a Ph.D. in Immunology from University College London.  She also obtained an Associate Certificate in Project Management in 2005 from The George Washington University.



Richard Warburg, Ph.D.

Head of Intellectual Property

Dr. Richard Warburg is Head of Intellectual Property at ADC Therapeutics and Managing Director of Intellectual Property & Licensing for Auven Therapeutics.

Previously, Dr. Warburg was a partner at the law firms of Foley & Lardner LLP and Lyon & Lyon, and a law clerk with Fish & Richardson. He has over 25 years’ experience in intellectual property litigation, strategic counseling, licensing and patent prosecution.

Dr. Warburg graduated from Birmingham University, England, with a BSc and a Ph.D. in molecular biology. He completed a post-doctoral fellowship at Brandeis University, acting as an adjunct professor at Wellesley College, and an instructor at University of Massachusetts and attended Suffolk University law school.



Francesca Zammarchi, Ph.D.

Senior Cancer Biologist

Dr. Francesca Zammarchi is a Senior Cancer Biologist at ADC Therapeutics.

Dr. Zammarchi is experienced in cancer research and has published multiple papers in peer-reviewed international scientific journals.

Before joining ADC Therapeutics, Dr. Zammarchi spent eight years as a Research Associate in the Molecular Pharmacology and Chemistry Department of Memorial Sloan Kettering Cancer Center, New York. During this time she successfully contributed to the development and optimization of small molecule drugs for the targeted treatment of cancer. Subsequently she worked as Cancer Biologist at Spirogen Limited.

Dr. Zammarchi is a graduate from the University of Pisa where she received her Ph.D. in Experimental and Molecular Oncology.



Peter B. Corr, Ph.D.

Chairman of the Board

Jay Feingold, M.D., Ph.D.

Senior Vice President, Chief Medical Officer and Head of Oncology

Simon Chivers, Ph.D.

Head of Toxicology

Stephen Evans-Freke

Non Executive Director

Michael Forer

Executive Vice President and Vice Chairman

Maria Cincotta

Executive Director of Clinical Operations

Michael Forer

Executive Vice President and Vice Chairman, Director

Dulce Gonçalves

General Counsel and Corporate Secretary

David Ellis, Ph.D.

Head of Global Regulatory Affairs

Bahija Jallal, Ph.D.

Non Executive Director

Stéphane Henchoz

Finance Director

Prof. John Hartley

Advisor

Chris Martin

Chief Executive Officer

Chris Martin

Chief Executive Officer

Karin Havenith, Ph.D.

Principal Bio Analytical Scientist

Jacques Theurillat

Non Executive Director

Michael Mulkerrin, Ph.D.

Vice President, Head of CMC

Shui He

Head of Biometrics

Barrie Ward, Ph.D.

Non Executive Director

Patrick Van Berkel, Ph.D.

Senior Vice President Research & Development

Richard Onyett

Vice President Business Development

Lisa Skelton, Ph.D.

Head of Project Management

Richard Warburg, Ph.D.

Head of Intellectual Property

Francesca Zammarchi, Ph.D.

Senior Cancer Biologist

Dr. Peter B. Corr is the Chairman of the Board of ADC Therapeutics and Co-Founder and Managing General Partner of Auven Therapeutics Management. He retired from Pfizer Inc. in December 2006 where he was Senior Vice President for Science and Technology.

Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development; and Senior Vice President, Discovery Research, at Monsanto/Searle and then as President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis. He spent 18 years at Washington University in St. Louis as Professor, Department of Medicine (Cardiology) and Department of Pharmacology and Molecular Biology.

He has held a number of Chairmanships including the Science & Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA); the PhRMA Foundation Board of Directors; and the Hever Group.

Dr. Corr is a past Governor and Chair of the New York Academy of Sciences, a member of the Board of Regents of Georgetown University and a Chairman of the Board of the International Partnership for Microbicides and of the Critical Path Institute. Dr. Corr also served on the boards of Furiex Pharmaceuticals, Inc., Global Edit, Inc., and the African Leadership Congress.



Dr. Jay Feingold is Senior Vice President, Chief Medical Officer and Head of Oncology Clinical Development of ADC Therapeutics.

Dr. Feingold has shared his career between the academic medicine and the pharmaceutical industry.  Before joining ADC Therapeutics, Dr. Feingold was Vice President of US Medical Affairs and Chairman of the Global Medical Affairs Oversight Committee at Daiichi Sankyo.

Dr. Feingold was previously Vice President of Global Oncology Clinical Development and Global Therapy Area Director of Oncology at Wyeth. Before joining Wyeth, Dr. Feingold was a member of the Departments of Medicine and Pediatrics and Associate Director of the Bone Marrow Transplant Program at the University of Connecticut overseeing the Alternative Donor and Pediatric Transplant Programs.

Dr. Feingold received his M.D. and Ph.D. degrees from the Albert Einstein College of Medicine and trained in Pediatrics and Pediatric Hematology and Oncology at the UCLA Center for the Health Sciences.



Simon Chivers is Head of Toxicology at ADC Therapeutics.

Dr. Chivers has extensive experience in the pharmaceutical and biotech industry, specializing in the safety assessment, development of protein and antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. Chivers spent six years with Novartis, most recently as Executive Director and Global Head of Biologics Safety Assessment, responsible for the non-clinical development of the Novartis biologics portfolio. Prior to Novartis he was a senior non-clinical safety assessment expert at AstraZeneca, working closely with MedImmune.  In addition, Dr. Chivers has held leadership roles at Syngenta BioPharma, Syngenta CTL and Quintiles.

Dr. Chivers has a degree in Pharmacology from University College London and a Ph.D. in Applied Pharmacology from Imperial College London.



Stephen Evans-Freke is Non Executive Director of ADC Therapeutics and Co-Founder and Managing General Partner of Auven Therapeutics.  Mr. Evans-Freke has been associated with the biotechnology industry for over 35 years as an investment banker, asset manager, entrepreneur, company CEO, and venture capitalist. During the 1980s, he was lead investment banker to Genentech, AMGEN, Centocor, and a number of other leading biotech companies. During this period, Mr. Evans-Freke served as President of PaineWebber Development Corporation and later a member of PaineWebber Inc.'s Board of Directors.

In 1990 Mr. Evans-Freke founded Selectide Corporation, where he served as Chairman until its sale to Hoechst in 1994. In 1991 he founded SUGEN, a drug discovery company, and served as Chairman and Chief Executive Officer through it’s IPO in 1995 until it’s sale to Pharmacia in 1999. Mr. Evans-Freke was also a co-founder of Fibrogen, Inc., Royalty Pharma AG, and CIBUS Global LLC, serving as Chairman of the latter until 2013.

Mr. Evans-Freke serves on the 800th Anniversary Appeal Board of Cambridge University, from which he holds a Degree in Law, and also on the Board of the Christopher and Dana Reeve Foundation.



Michael Forer is Vice Chairman of ADC Therapeutics having served as its Chief Executive Officer from formation to June 2015, and is also Executive Vice President focused on its public markets capital strategy, business and finance activities. Mr. Forer is also a Managing Director of Auven Therapeutics.

Prior to joining ADC Therapeutics and Auven, Mr. Forer co-founded Rosetta Capital Limited, a London private equity firm focused on the life science sector. Prior to Rosetta, Mr. Forer was an investment manager at Rothschild Asset Management where he was responsible for making and managing private equity investments in North America and Europe in the life science sector. Mr. Forer has also been an active corporate finance and M&A advisor to private and public life science based clients.

Mr. Forer has a law degree from the University of British Columbia (1990), a diploma in International Business from the University of Copenhagen (1987), and a bachelor of economics from the University of Western Ontario (1986). Mr. Forer is called to the Bar for the Law Society of Upper Canada.



Maria Cincotta is Executive Director of Clinical Operations at ADC Therapeutics.

Ms. Cincotta has extensive experience in managing and leading clinical programs within the pharmaceutical industry, and was formerly a clinical research and operations consultant focused in oncology for both biotech and pharmaceutical companies.  Prior to this, she was a Global Clinical Program Leader in the oncology division at Wyeth, with responsibility for early and late stage assets, managing the Torisel™ (temsirolimus) clinical research program through global product registration for renal cell carcinoma and mantle cell lymphoma.

Ms. Cincotta received her undergraduate degree from the University of Massachusetts, and a MS in Clinical Investigation from the MGH Institute of Health Professions in Boston Massachusetts.



Michael Forer is Vice Chairman and Director of ADC Therapeutics having served as its Chief Executive Officer from formation to June 2015, and is also Executive Vice President focused on its public markets capital strategy, business and finance activities.  Mr. Forer is also a Managing Director of Auven Therapeutics.

Prior to joining ADC Therapeutics and Auven, Mr. Forer co-founded Rosetta Capital Limited, a London private equity firm focused on the life science sector.  Prior to Rosetta, Mr. Forer was an investment manager at Rothschild Asset Management where he was responsible for making and managing private equity investments in North America and Europe in the life science sector.  Mr. Forer has also been an active corporate finance and M&A advisor to private and public life science based clients.

Mr. Forer has a law degree from the University of British Columbia, a diploma in International Business from the University of Copenhagen, and a bachelor of economics from the University of Western Ontario. Mr. Forer is called to the Bar for the Law Society of Upper Canada.



Dulce Gonçalves is General Counsel and Corporate Secretary of ADC Therapeutics.

Ms. Gonçalves made the vast majority of her career in the pharmaceutical industry and brings broad expertise in all fields of health science, from research and development activities, to technical operations and manufacturing, regulatory affairs, medical and marketing activities, business development & licensing, healthcare compliance, and launch and commercialization of pharmaceutical products.

Ms. Gonçalves was most recently Senior Legal Counsel, Global Product Strategy and Commercialization, at Novartis.  Prior to her role at Novartis, Ms. Gonçalves served as Senior Legal Counsel at Celgene International and UCB SA. She was also previously International Legal Counsel at France Telecom (now Orange) International Networks and Carriers division.

Ms. Gonçalves holds a Masters degree in Business Law and Foreign Languages from the University Pierre Mendès France of Grenoble, France and a LLM in International Business Law from the University of Bourgogne, Dijon, France.



Dr. David Ellis is Head of Global Regulatory Affairs at ADC Therapeutics.

Dr. Ellis has very extensive experience in global regulatory affairs, holding positions in both Europe and the USA. Dr. Ellis is experienced in the global development and registration of small molecule and biologic therapies.

Prior to joining ADC Therapeutics, Dr. Ellis was Vice President of Regulatory Affairs for Aptalis Pharma US. Prior to this Dr. Ellis held positions at Cephalon and previously Wyeth Pharmaceuticals, where he was Global Therapeutic Area Head for Oncology & Hemophilia, and Inflammation & Immunology.

Dr. Ellis is a graduate of the University of Nottingham, UK, where he received his PhD in Molecular Biology.



Dr. Bahija Jallal is Non Executive Director of ADC Therapeutics, as well as Executive Vice President of AstraZeneca and Head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK.  She is a member of the senior executive team at AstraZeneca reporting to the CEO. Dr. Jallal joined MedImmune in March 2006.

Dr. Jallal is a member of the Board of Trustees of the Johns Hopkins University.  She is also a member of the Board of Directors of the University of Maryland Health Sciences Research Park Corporation, a non-profit organization that manages biomedical research development at the BioPark.

Dr. Jallal has authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory board member of the Healthcare Business Women’s Association. She was recognized as one of FierceBiotech’s 2011 Women in Biotech and in 2012, she received Washington Business Journal’s Women Who Mean Business award.

Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as Vice President, Drug Assessment and Development, and successfully established the company’s translational medicine group; and previously at Sugen, Inc. where she held positions of increasing responsibility leading to Senior Director, Research.

Dr. Jallal received a master’s degree in biology from the Université de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.



Stéphane Henchoz is Finance Director at ADC Therapeutics.

Mr. Henchoz spent all his career in finance in the pharmaceutical industry.

Prior to joining ADC Therapeutics, Mr. Henchoz held senior leadership roles at Merck Serono most recently as Controlling Manager for the Research and Development Function. While at Merck Serono, he also served in various finance functions, including Financial Controller for the IT Function in Geneva, Associate Manager at the Corporate Strategic Management Department in Geneva, and Regional Financial Analyst for the Latin America Region in Uruguay.

Mr. Henchoz has a Bachelor in Economics and Finance from the HEG (Haute Ecole de Gestion) in Geneva.



Prof. John Hartley is advisor to ADC Therapeutics and Professor of Cancer Studies at UCL. He was one of the founders of Spirogen.

Prof. Hartley is also Director of the Cancer Research UK Drug-DNA Interactions Research Group and Co-Lead of the UCL Experimental Cancer Medicine Centre. Prior to joining UCL he was a Visiting Fellow at the National Cancer Institute, USA and an Alberta Heritage Research Fellow at the University of Alberta, Canada.

John has a B.Sc. in Biochemistry and a Ph.D. in Experimental Chemotherapy from the University of Manchester. He has over 280 publications in the fields of molecular and clinical pharmacology, DNA damage and repair, drug design and development, and cancer therapeutics. He is a Fellow of both the Royal Societies of Biology and Chemistry and is an Honorary Member of the Royal College of Radiologists. He is also Chair of the Protocol Safely and Review Board of Cancer Research UK.



Dr. Chris Martin is Chief Executive Officer and Director of ADC Therapeutics. He played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding.

Previously Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca, in October 2013, at which point he became both a member of MedImmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group.

Prior to the acquisition by AstraZeneca MedImmune, Dr. Martin led numerous Spirogen collaboration transactions, including agreements with two of the leading industry players in the antibody drug conjugate area, Genentech and Seattle Genetics.

He is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow.



Dr. Chris Martin is Chief Executive Officer and Director of ADC Therapeutics. He played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding.

Previously Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of AstraZeneca, in October 2013, at which point he became both a member of MedImmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group.

Prior to the acquisition by AstraZeneca MedImmune, Dr. Martin led numerous Spirogen collaboration transactions, including agreements with two of the leading industry players in the antibody drug conjugate area, Genentech and Seattle Genetics.

He is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow.



Dr. Karin Havenith is Principal BioAnalytical Scientist at ADC Therapeutics.

Dr. Havenith is experienced in the biotech industry, specialized in the development and validation of non-clinical and clinical bio-analytical assays, as well as CMC related bio-analytical assays for antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. Havenith was at Crucell Holland BV (Johnson & Johnson Company) as Biologicals Assay Manager for antibody-based therapeutics, and prior to Crucell she worked for more than seven years at Genmab, as Principal Scientist on cancer-target related antibody-based therapeutics. Prior to the biotech industry, Dr. Havenith spent more than 15 years in  academia at TNO Prevention & Health in Leiden, NL, St. Jude Children’s Hospital, Memphis TN, US, and Vrije University, Amsterdam, NL.

Dr. Havenith graduated with her M.Sc. in Animal Husbandry from the University of Wageningen, NL, and obtained a Ph.D. in Cell Biology & Immunology from the Vrije University, Amsterdam, NL.



As an independent Non Executive Director, Mr. Theurillat brings to the Board extensive experience in strategy development, finance and commercial operations.

He has been CEO of Ares Life Sciences AG and previously served as CEO and Chairman of Albea Pharmaceuticals AG.  He also had an extensive career at Serono, which spanned roles such as Chief Financial Officer, Deputy Chief Executive Officer and Senior Executive Vice President, Strategic Corporate Development.

Mr. Theurillat holds Bachelor of Law Degrees from Madrid University and Geneva University, a Master’s Degree in Finance from Centro Estudios Financieros, Madrid and a Swiss Federal Tax Expert Diploma.

Dr. Michael Mulkerrin is Vice President, Head of CMC (Chemistry Manufacturing and Control) of at ADC

Dr. Mulkerrin has extensive industry experience in biologics manufacturing. Prior to joining ADC Therapeutics, he held the position of Vice President, Process Development and Manufacturing at OncoMed Pharmaceuticals.

Prior to OncoMed, Dr. Mulkerrin was the Senior Director in Process Sciences at Amgen heading Analytical Biochemistry.   He also served in leadership positions in the development of therapeutic monoclonal antibody projects at Genentech and Abgenix. In 2010, Dr. Mulkerrin was elected to the USP Council of Experts, and is Chairman of the Biologics Monographs – Proteins Expert Committee.

Dr. Mulkerrin has a B.S. in Biochemistry from the University of Massachusetts, Amherst, and a Ph.D. in Biochemistry from the University of Georgia, Athens.



Dr. He is Head of Biometrics at ADC Therapeutics.

Dr. He has experience in the pharmaceutical and biotechnology industries.

Prior to joining ADC Therapeutics, Dr. He was Director of Biostatistics and Programming at Incyte Corporation, responsible for Jakafi ® (ruxolitinib), the first JAK inhibitor, submission for myelofibrosis,  and polycythemia vera. Prior to Incyte Corporation, Dr. He held positions at Sanofi, where he played an important role in the development of Jevtana ® (cabazitaxel), Taxotere ® (Docetaxel).

Dr. He is a graduate of the University of Pittsburgh, where he received his PhD in Biostatistics.



Dr. Ward is Non Executive Director of ADC Therapeutics and brings a tremendous wealth of leadership skills and experiences to the Board of the company.

Dr. Ward is currently a member of the Board of BergenBio AS and of the Board of Supervisory Directors of Pharming Group N.V. He also served as Chief Executive Officer of KuDOS Pharmaceuticals Ltd. from 1999 until 2006 when the company was acquired by AstraZeneca, and Chief Executive Officer and Chairman of the Board of Directors of Virus Research Institute, Inc. He previously was Chairman of CellCentric Ltd and a member of the Board of Cancer Research Technology Ltd.

Earlier in his career, Dr. Ward worked in research for Glaxo Group Research, where he became Director of the Microbiology Division of Glaxo Research and Development Ltd.

Dr. Ward holds a B.Sc and a Ph.D. in microbial biochemistry from the University of Bath, England.



Dr. van Berkel is Senior Vice President Research & Development of ADC Therapeutics.

Dr. van Berkel has conducted his entire career in the biotech industry, specializing in the development of antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. van Berkel spent more than nine years with Genmab as Director of Technology of Antibody Technology and most recently as Vice President of Chemistry, Manufacturing and Control Research & Development.

Dr. van Berkel has a chemistry degree from the University of Nijmegen, The Netherlands, and did his thesis at the University of Leiden, The Netherlands.



Richard Onyett is Vice President Business Development at ADC Therapeutics.

Mr. Onyett has over 40 years of experience in the pharmaceutical and biotech industries.  Prior to joining ADC Therapeutics, Mr. Onyett was Commercial Director at Spirogen Limited responsible for business development with respect to licensing of PBD cytotoxin payload technology to major pharma and specialized biotech companies worldwide.

Prior to Spirogen, Mr. Onyett ran his own successful commercial development consultancy and subsequently served as Senior Vice President of Business or Corporate Development for a number of biotech companies based in the US, Europe and UK including KuDOS Pharmaceuticals where he was responsible for the BD strategy and activity that lead to the sale of KuDOS Pharmaceuticals to AstraZeneca in 2006.

Mr. Onyett began his career as International Product Manager with ICI Pharmaceuticals (now AstraZeneca) and subsequently as Director of Business Development for SmithKline and French (now GSK).

Mr. Onyett graduated with a B. Sc. (hons.) in Biological Sciences from the University of Nottingham, England and a M.Sc.in General Virology from the University of Birmingham, England.



Lisa Skelton is Head of Project Management at ADC Therapeutics.

Dr. Skelton spent most of her career in the pharmaceutical industry and has led numerous cross functional teams developing drugs, and in particular antibody-based therapeutics.

Prior to joining ADC Therapeutics, Dr. Skelton was Associate Director, Program Management at Norgine Ltd.  Prior to Norgine, Dr. Skelton was Senior Project Manager at Amgen and at Antisoma Research Limited and Project Manager at UCB Celltech.

Dr. Skelton graduated with a B.Sc. (hons.) in Immunology from NESCOT and obtained a Ph.D. in Immunology from University College London.  She also obtained an Associate Certificate in Project Management in 2005 from The George Washington University.



Dr. Richard Warburg is Head of Intellectual Property at ADC Therapeutics and Managing Director of Intellectual Property & Licensing for Auven Therapeutics.

Previously, Dr. Warburg was a partner at the law firms of Foley & Lardner LLP and Lyon & Lyon, and a law clerk with Fish & Richardson. He has over 25 years’ experience in intellectual property litigation, strategic counseling, licensing and patent prosecution.

Dr. Warburg graduated from Birmingham University, England, with a BSc and a Ph.D. in molecular biology. He completed a post-doctoral fellowship at Brandeis University, acting as an adjunct professor at Wellesley College, and an instructor at University of Massachusetts and attended Suffolk University law school.



Dr. Francesca Zammarchi is a Senior Cancer Biologist at ADC Therapeutics.

Dr. Zammarchi is experienced in cancer research and has published multiple papers in peer-reviewed international scientific journals.

Before joining ADC Therapeutics, Dr. Zammarchi spent eight years as a Research Associate in the Molecular Pharmacology and Chemistry Department of Memorial Sloan Kettering Cancer Center, New York. During this time she successfully contributed to the development and optimization of small molecule drugs for the targeted treatment of cancer. Subsequently she worked as Cancer Biologist at Spirogen Limited.

Dr. Zammarchi is a graduate from the University of Pisa where she received her Ph.D. in Experimental and Molecular Oncology.



Contact

Head Office

Biopôle
Route de la Corniche 3B
1066 Epalinges, Switzerland
+41 21 653 02 00
View map
How to find us

R&D Laboratories

QMB Innovation Centre
42 New Road
London, E1 2AX, UK
+44 (0)20 3021 9401
View map

Clinical Development

430 Mountain Avenue, 4th Floor
Murray Hill, NJ 07974, USA
+1 908 731-5556
View map

For General Enquiries

Email: info@adctherapeutics.com